| __timestamp | Galapagos NV | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 111110000 | 12122000 |
| Thursday, January 1, 2015 | 129714000 | 13380000 |
| Friday, January 1, 2016 | 139574000 | 21221000 |
| Sunday, January 1, 2017 | 218502000 | 26887000 |
| Monday, January 1, 2018 | 322876000 | 27863000 |
| Tuesday, January 1, 2019 | 427320000 | 55908000 |
| Wednesday, January 1, 2020 | 523667000 | 59392000 |
| Friday, January 1, 2021 | 491707000 | 69012000 |
| Saturday, January 1, 2022 | 515083000 | 36082000 |
| Sunday, January 1, 2023 | 241294000 | 24537000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, research and development (R&D) is the lifeblood of innovation. Over the past decade, Galapagos NV and Ligand Pharmaceuticals Incorporated have demonstrated contrasting strategies in their R&D investments. Galapagos NV, a Belgian biotech firm, has consistently outpaced Ligand in R&D spending, with an average annual budget nearly nine times larger. Notably, Galapagos NV's R&D expenses peaked in 2020, reaching over 500% of their 2014 levels, before a significant drop in 2023. Meanwhile, Ligand Pharmaceuticals, based in the U.S., showed a steady increase, peaking in 2021 with a 470% rise from 2014. This divergence highlights the varying approaches to innovation and growth within the sector. As the industry faces new challenges, these investment patterns may shape the future landscape of pharmaceutical breakthroughs.
Eli Lilly and Company or Ligand Pharmaceuticals Incorporated: Who Invests More in Innovation?
Comparing Innovation Spending: Amgen Inc. and Ligand Pharmaceuticals Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Galapagos NV
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ligand Pharmaceuticals Incorporated
Research and Development Investment: Ionis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Galapagos NV
Analyzing R&D Budgets: Amneal Pharmaceuticals, Inc. vs Galapagos NV
Comparing Innovation Spending: Apellis Pharmaceuticals, Inc. and Galapagos NV
Research and Development: Comparing Key Metrics for Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
CRISPR Therapeutics AG vs Galapagos NV: Strategic Focus on R&D Spending
R&D Spending Showdown: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Comparing Innovation Spending: Ligand Pharmaceuticals Incorporated and Evotec SE